Compare British American Tobacco PLC (BTI) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
British American Tobacco PLC vs Ginkgo Bioworks Holdings Inc — how do they compare? British American Tobacco PLC trades at $56.07 (market cap $122.36B), while Ginkgo Bioworks Holdings Inc trades at $7.43 (market cap $505.73M). The key difference: British American Tobacco PLC is far larger — about 241.9× Ginkgo Bioworks Holdings Inc's market cap, and British American Tobacco PLC pays a 5.88% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| BTI | DNA | |
|---|---|---|
Market Cap | $122.36B | $505.73M |
Sector | Consumer Staples | Health |
52-Week High | $66.70 | $16.14 |
52-Week Low | $50.39 | $5.48 |
Enterprise Value | $166.31B | $607.68M |
Dividend Yield | 5.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BTI trades at $55.93, down 1.96% today, with a bearish technical signal and mixed earnings history. The company maintains strong profitability with an 83.56% gross margin and 24.99% net income margin, supported by a P/E of 14.48. Recent news highlights strategic tech partnerships and workforce restructuring to drive efficiency.
The outlook is cautious due to declining cash flow and regulatory risks, but the 5%+ dividend yield and analyst buy consensus (66.7%) offer value. Upside depends on successful transition to next-generation products, while core combustible declines and debt levels pose challenges.
Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.
DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About British American Tobacco PLC
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
